retatrutide triple agonist obesity trial ⭐️topline results from TRIUMPH-1, a Phase 3 clinical evaluating #retatrutide, an investigational GIP / GLP-1 / glucagon hormone receptor agonist, in adults with or “overweight” The most intensive medical obesity

But for someone with a smaller percentage of their body weight to lose, or with health conditions, compounded medications might introduce unnecessary risk, she said

This triple-agonist mechanism is unlike older treatments, which generally focus on a single pathway

A retatrutida uma molcula com efeito triplo agonista, que atua na promoo da saciedade e controle da glicemia

Made in the EU under strict standards: produced according to GMP and ISO guidelines for purity, safety, and effectiveness

For context, authorised incretin-based injectable medicines such as semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro) have defined refrigerated storage conditions set out in their respective UK SmPCs